Arabzadeh Somaye, Zeinoddini Atefeh, Mostafavi Seyed-Ali, Hamedi Mehdi, Ehyaii Abolfazl, Ghaleiha Ali, Zeinoddini Arefeh, Akhondzadeh Shahin
Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Behavioral Disorders and Substance Abuse Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Iran J Psychiatry. 2018 Jan;13(1):1-9.
Although the pathogenesis of schizophrenia is still uncertain, a variety of predisposing mechanisms have been implicated including inflammatory cascades. The present study was conducted to investigate the effectiveness of acetaminophen as a cyclooxygenase inhibitor in treating patients with schizophrenia. A double-blind clinical trial was performed on 52 patients with chronic schizophrenia. Patients received risperidone (up to 6 mg/day) plus either acetaminophen (975mg/day) or placebo. Psychotic symptoms were assessed by the Positive and Negative Syndrome Scale (PANSS) at the onset of the trial, and at 2, 4, 6, and 8 weeks post therapy. Compared to the placebo group, the acetaminophen group showed no significant difference in any subtypes of PANSS. Moreover, the side effect profiles of the 2treatment regimens were not significantly different. Acetaminophen adjuvant to risperidone showed no significant effect in ameliorating symptoms of schizophrenia.
The trial was registered at the Iranian Registry of Clinical Trials (registration number: IRCT201410251556N67).
尽管精神分裂症的发病机制仍不明确，但包括炎症级联反应在内的多种易感机制已被牵连其中。本研究旨在探讨对乙酰氨基酚作为一种环氧化酶抑制剂治疗精神分裂症患者的有效性。对52例慢性精神分裂症患者进行了一项双盲临床试验。患者接受利培酮（最高6毫克/天）加对乙酰氨基酚（975毫克/天）或安慰剂治疗。在试验开始时以及治疗后2周、4周、6周和8周，通过阳性和阴性症状量表（PANSS）评估精神症状。与安慰剂组相比，对乙酰氨基酚组在PANSS的任何亚型上均无显著差异。此外，两种治疗方案的副作用情况也无显著差异。利培酮加用对乙酰氨基酚在改善精神分裂症症状方面无显著效果。
该试验在伊朗临床试验注册中心注册（注册号：IRCT201410251556N67）。
Zotero 插件